Macrolide antibiotics: current and future uses

Bibliography

• BRYSKIER A: New research in macrolides and ketolides since 1997. Exp. Opin. Invest. Drugs (1999) 8:1171–1194.
   PubMedGoogle Scholar
• LABRO MT: Cellular accumulation of macrolide antibiotics. Intracellular bioactivity. In: Macrolide Antibiotics. Schönfeld W, Kirst H (Eds), Birkhäuser Verlag AG (2002):37–52
   Google Scholar
• BRYSKIER A, AGOURIDAS C, CHANTOT JF: New medical targets for macrolides. Exp. Opin. Investig. Drugs. (1994) 3:405–410.
   Google Scholar
• BLONDEAU JM, DECAROLIS E, METZLER KL, HANSEN GT: The Macrolides. Expert. Opin. Investig. Drugs (2002) 11(2):189–215.
   PubMed Web of Science ®Google Scholar
• ••An extended review of the anti-infectiveproperties and clinical applications of macrolides.
   Google Scholar
• Macrolide Antibiotics. Schönfeld W, Kirst H (Eds), Birkhäuser Verlag AG (2002).
   Google Scholar
• ••An exhaustive book on the modern andclassical aspects of macrolides.
   Google Scholar
• LABRO MT: Antiinflammatory activity of macrolides: a new therapeutic potential? Antimicrob. Chemother (1998)41 (Suppl. B):37–46.
   Google Scholar
• LABRO MT: Immunological effects of macrolides. Curr. Opin. Infect. Dis. (1998) 11:681–688.
   PubMed Web of Science ®Google Scholar
• •An update on the non-antibiotic aspects of macrolides.
   Google Scholar
• CULIC 0, ERAKOVIC V, PARNHAM MJ:Anti-inflammatory effects of macrolide antibiotics. Ear: J. Pharmacy]. (2001) 429:209–229.
   Google Scholar
• LABRO MT: Antibiotics as anti-inflammatory drugs. Curt: Opin. Investig. Drugs (2002) 3:61–68.
   PubMedGoogle Scholar
• •A review of past and future prospects of anti-inflammatory antibiotics.
   Google Scholar
• JAFFE A, BUSH A: Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol (2001) 31:464–473.
   PubMed Web of Science ®Google Scholar
• GURFINKEL E, BOZOVICH G, BECK E, TESTA E, LIVELLARA B, MAUTNER B: Treatment with the antibiotic roxithromycin in patients with non-Q-wave coronary syndromes. The final report of the ROXIS study. Ear: Heart J. (1999) 20:89–92.
   PubMedGoogle Scholar
• •CAD and macrolides: the controversy begins.
   Google Scholar
• GUPTA S, LEATHAN EW, CARRINGTON D, MENDALL MA, KASKI JC, CAMM A: Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infections. Circulation (1997) 96:404–407.
   PubMed Web of Science ®Google Scholar
• SINISALO J, MATTILA K,VALTONEN V et al.: Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation. (2002) 105:1555–1560.
   Google Scholar
• ZAHN R, SCHNEIDER S, FRILLING B et al.: Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation (2003) 107(9):1253–1259.
   PubMedGoogle Scholar
• CERCEK B, SHAH PK, NOC M et al: Effect of long-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet (2003) 361:809–813.
   PubMed Web of Science ®Google Scholar
• O'CONNOR CM, DUNNE MW, PFEFFER MA et al.: Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 290:1459–1466.
   Google Scholar
• •The results of the largest clinical trial yet published on the efficacy of macrolides (azithromycin) in the prevention of CAD.
   Google Scholar
• JACKSON LA: Description and status of the azithromycin and coronary events study (ACES). Infect. Dis. (2000)181\(Suppl. 3): S579–S581.
   Google Scholar
• MUHLESTEIN JB, ANDERSON JL, CARLQUIST JF et al: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease. Primary clinical results of the ACADEMIC study. Circulation (2000) 102:1755–1760.
   PubMed Web of Science ®Google Scholar
• STONE AF, MENDALL MA, KASKI JC et al: Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation (2002) 106:1219–1223.
   PubMed Web of Science ®Google Scholar
• NEUMANN F, KASTRATI A, MIETHKE T et al.: Treatment of Chlamydia pneumoniae infection withroxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet (2001) 357:2085–2089
   PubMed Web of Science ®Google Scholar
• VAMMEN S, LINDHOLT JS, OSTERGAARD L, FASTING H, HENNEBERG EW: Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br. I Surg. (2001) 88(8):1066–1072
   PubMed Web of Science ®Google Scholar
• LUCHSINGE JA, PABLOS-MENDEZ A,KNIRSCH C, RABINOWITZ D,SHEA S: Relation of antibiotic use to risk of myocardial infarction in the general population. Am. j Cardiol. (2002) 89:18–21.
   PubMedGoogle Scholar
• KARTER AJ, THOM DH, LIU J, MOFFET HH, FERRARA A, SELBY JV: Use of antibiotics is not associated with decreased risk of myocardial infarction among patients with diabetes. Diabetes Care (2003) 26(7):2100–2106.
   PubMedGoogle Scholar
• HIGGINS JP: Chlamydia pneumoniae and coronary artery disease: the antibiotic trials. Mayo Gin. Proc. (2003) 78:321–332.
   PubMedGoogle Scholar
• BRASSARD P, BOURGAULT C, BROPHY J, KEZOUH A, SUISSA S: Antibiotics in primary prevention of stroke in the elderly. Stroke (2003) 34:163–166.
   Google Scholar
• WIESLI P, CZERWENKA W, MENTICONI A et al: Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation (2002) 105(22):2646–2652.
   PubMed Web of Science ®Google Scholar
• PISLARU SV, VAN DE WERF F: Antibiotic therapy for coronary artery disease can a WIZARD change it all? JA/VIA (2003) 290:1515–1516.
   Google Scholar
• GIEFFERS J, FOLLGRAF H, JAHN J et al.: Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation (2001) 103:351–356.
   PubMed Web of Science ®Google Scholar
• •An in vitro (in vivo) model sustaining the controversies on the antibacterial/anti-inflammatory (?) potential of macrolides in CAD.
   Google Scholar
• KUTTLIN A, ROBLIN PM, HAMMERSCHLAG MR: Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-ainfection model. Antimicrob. Agents Chemother. (2002) 46:409–412.
   PubMedGoogle Scholar
• BLACK PN, SCICCHITANO R, JENKINS CR et al.: Serological evidence of infection with chlamydia pneumoniae is related to the severity of asthma.aEur. Respir. 15:254–259.
   Google Scholar
• CAZZOLA M, SALZILLO A,DIAMARE F: Potential role of macrolides in the treatment of asthma. Monaldi Arch. Chest Dis. (2000) 55:231–236.
   PubMedGoogle Scholar
• AVILA PC, BOUSHEY HA: Macrolides, asthma, inflammation, and infection. Ann. Allergy Asthma Immunol. (2000) 84:565–568.
   PubMed Web of Science ®Google Scholar
• AMAYASU H, YOSHIDA S, EBANA S et al.: Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann. Allergy Asthma Immunol. (2000) 84:594–598.
   PubMed Web of Science ®Google Scholar
• TAKIZAWA H, DESAKI M,OHTOSHI T et atrythromycin and clarithromycin attenuate cytokin-induced endotheli-1 expression in human bronchial epithelial cells. Eur. Respic (1998) 12:57–63.
   PubMedGoogle Scholar
• NOMA T, OGAWA N: Roxithromycin enhances lymphocyte apoptosis in Dermatophagoides-sensitive childhood asthma. I Allergy Clin. Immunol. (2003) 111:646–647.
   PubMedGoogle Scholar
• NOMA T, AOKI K, HAYASHI M, YOSHIZAWA I, KAWANO Y: Effect of roxithromycin on T lymphocyte proliferation and cytokine production elicited by mite antigen. Internat. Immunopharmacol. (2001) 1:201–10.
   PubMedGoogle Scholar
• SPAHN JD, FOST DA, COVAR R et al.:Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study.aAnn. Allergy Asthma Immunaol (2001) 87:501–505.
   PubMed Web of Science ®Google Scholar
• RICHELDI L, FERRARA G, FABBRIL M, GIBSON PG: Macrolides for chronic asthma. Cochrane Database Syst. Rev (2002) 1:CD 002997.
   Google Scholar
• LEIPER K, MORRIS Al, RHODES JM: Open label trial of oral clarithromycin in active Crohn's disease. Ailment. Pharmacol. The]: (2000) 14:801–806.
   PubMedGoogle Scholar
• YAMANAKA Y, TAMARI M, NAKAHATA T, NAKAMURA Y: Gene expression profiles of human small airway epithelial cells treated with low doses of 14- and 16-membered macrolides.Biochem. Biophys. Res. Comm. (2001) 287:198-203.A fundamental approach on the modulation of cell functions by macrolides.
   Google Scholar
• JAFFE A, ROSENTHAL M: Macrolides in the respiratory tract in cystic fibrosis. R. Soc. Med. (2002) 95\(Suppl. 41):27–31.
   Google Scholar
• GAYLOR AS, REILLY JC: Therapy with macrolides in patients with cystic fibrosis. Pharmacother. (2002) 22:327–335.
   Google Scholar
• CAREY KW, ALWAMI A,DANZIGER LH, RUBINSTEIN I: Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest (2003) 123:261–265.
   PubMed Web of Science ®Google Scholar
• ••A recent review on the anti-inflammatorytherapeutic efficacy of macrolides in lung diseases.
   Google Scholar
• CERVIN A: The anti-inflammatory effectof erythromycin and its derivatives with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol. (2001) 121:83–92.
   PubMed Web of Science ®Google Scholar
• YAMADA G, IGARASHI T, ITOH E, TANAKA H, SEKINE K, ABE S: Centrilobular nodules correlate with air trapping in diffuse panbronchiolitis during erythromycin therapy. Chest (2001) 1120:198–202.
   Google Scholar
• KADOTA J, MUKAE H, ISHII H et al.:Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respic Med. (2003) 97(7):844–850.
   PubMed Web of Science ®Google Scholar
• HIRATSUKA T, MUKAE H, IIBOSHI H et al.: Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax (2003) 58:425–430.
   PubMed Web of Science ®Google Scholar
• MORIKAWA T, KADOTA JI, KOHNO S,KONDO T: Superoxide dismutase in alveolar macrophages from patients with diffuse panbronchiolitis. Respiration (2000) 67:546–551.
   PubMedGoogle Scholar
• KANEKO Y, YANAGIHARA K, SEKI M et al.: Clarithromycin inhibits overproduction of muc Sac core protein in murine model of diffuse panbronchiolitis. Am. I Physiol. Lung Cell. Mol. Physiol. (2003) 285:L847–L853.
   Google Scholar
• EQUI A, BALFOUR-LYNN IM, BUSH A,ROSENTHAL M:. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet (2002) 360:978–984.
   PubMed Web of Science ®Google Scholar
• •An encouraging clinical trial in CE
   Google Scholar
• WOLTER J, SEENEY S, BELLS, BOWLERS, MASEL P,MCCORMACH J: Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax (2002) 57:212–216.
   PubMed Web of Science ®Google Scholar
• ORDONEZ CL, STULBAR GM, GRUNDLAND H, LIU JT,BOUSHEY HA: Effects of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediam. Pulmonol. (2001) 32:29–37.
   PubMed Web of Science ®Google Scholar
• SOUTHERN KW, BARKER PM,SOLIS: A: Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev (2003) 3:CD002203.
   Google Scholar
• SCHONI MH: Macrolide antibiotic therapy in patients with cystic fibrosis. Swiss Med. Wkly (2003) 133(21-22):297–301.
   PubMed Web of Science ®Google Scholar
• TSANG KW, HO PI, CHAN KN et al.:A pilot study of low-dose erythromycin in bronchiectasis. Eur: Respic (1999) 13:361–364.
   PubMed Web of Science ®Google Scholar
• KOH YY, LEE MH, SUN YH, SUNG KW, CHAE JH: Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur. Respic (1997) 10:994–999.
   PubMed Web of Science ®Google Scholar
• NAKAMURA H, FUJISHIMA S, INOUE T et al.: Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infections Eur. Resp. .1. (1999) 13:1371-1379.
   Google Scholar
• KAWAMURA M, ARAI Y, TANI M.: Improvement in right lung atelectasis (middle lobe syndrome) following administration of low-dose roxithromycin Respiration (2001) 68:210–214.
   Google Scholar
• MACLEOD CM, HAMID QA, CAMERON L, TREMBLAY C,BRISCO W: Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa Adv. Ther (2001) 18:75–82.
   Google Scholar
• YAMADA T, FUJIEDA S, MORI S, YAMAMOTO H, SAITO H: Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage.Am. Rhino]. (2000) 14:143–148.
   PubMedGoogle Scholar
• ENOMOTO F, ANDOU I, NAGAOKA I, ICHIKAWA G: Effect of new macrolides on the expression of adhesion molecules onneutrophils in chronic sinusitis.Auris Nasus Larynx. (2002) 29:267–269.
   PubMedGoogle Scholar
• NONAKA M, PAWANKAR R, TOMIYAMA S, YAGI T: A macrolide antibiotic, roxithromycin, inhibits the growth of nasal polyp fibroblasts. Am. J. Rhino]. (1999) 13:267–272.
   PubMedGoogle Scholar
• TAGAYA E, TAMAOKI J, KONDFO M, NAGAI A: Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest (2002) 122:213–218.
   PubMed Web of Science ®Google Scholar
• YAZAWA N, IHN H, YAMANE K, ETOH T, TAMAKI K. The successful treatment of prurigo pigmentosa with macrolide antibiotics. Dermatology (2001) 202:67–69.
   Google Scholar
• JANG HS, OH CK, CHA JH, CHO SH, KWON KS: Six cases of confluent and reticulated papillomatosis alleviated by various antibiotics. Am. Acad. Dermatol. (2001) 44:652–655.
   PubMedGoogle Scholar
• COOPER SM, POWELL J,WOJNAROWSKA F: Linear IgA disease: successful treatment with erythromycin. Clin. Exp. Dermatol. (2002) 27:677–679.
   PubMed Web of Science ®Google Scholar
• KOMINE M, TAMAKI K: An open trial of oral macrolide treatment for psoriasis vulgaris..j Dermatol. (2000) 27:508–512.
   PubMedGoogle Scholar
• SCHILLING F, WAGNER AD: Azithromycin: eine anti-inflammatorische wirksamkeit inn einsatz bei der chronischen rekurrierenden multifokalen osteomyelitis? Eine vorläufige Mitteilung Z Rheumatol. (2000) 59:352–353.
   Google Scholar
• •A new therapeutic potential for macrolides.
   Google Scholar
• IANARO A, IALENTI A, MAFFIA P et al.: Antiinflammatory activity of macrolide antibiotics. Pharmacol. Exp. Ther. (2000) 292:156–163.
   PubMed Web of Science ®Google Scholar
• MIYAJIMA M, SUGA M,NAGAKAWA K, ITO K, ANDO M: Effect of erythromycin on experimental extrinsic allergic alveolitis.aClin. Exp. Allergy(1999) 29:253–261.
   PubMed Web of Science ®Google Scholar
• LI Y, AZUMA A, TAKASHI S etal.: Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest (2002) 122:2137–2145.
   Google Scholar
• YOSHII T, MAGARA S, MIYAI D et at:Inhibitory effect of roxithromycin on the local levels of bone-resorbing cytokines in an experimental model of murineosteomyelitis. Antimicrob. Chemother:(2002) 50:289–292.
   Google Scholar
• DUONG M, SIMARD M,BERGERON Y, BERGERON MG: Kinetic study of the inflammatory response in Streptococcus pneumoniae experimental pneumonia treated with the ketolide HMR 3004. Antimicrob. Agents Chemother: (2001) 45:252–262.
   Google Scholar
• SAKAMOTO M, MIKASA K, MAJAMA T et al.: Anticachectic effect of clarithromycin for patients with unresectable non-small-cell lung cancer. Chemotherapy (2001) 47:444–451.
   PubMedGoogle Scholar
• •A new hope for lung cancer?
   Google Scholar
• DIMOPOULOS MA, TSATALAS C, ZOMAS A et al: Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin. Omni (2003) 30:265–269.
   Google Scholar
• COLEMAN M, LEONARD J, LYONS L,SZELENYI R, NIESVIZKY R: Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol. (2003) 30:270–274.
   PubMed Web of Science ®Google Scholar
• SAUTER C, BLUM S: Regression of lunglesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease. J. Clin. Oncol (2003) 26:92–94.
   PubMed Web of Science ®Google Scholar
• SASSA K, MIZUSHIMA Y, FUJISHITA T,00SAKI R, KOBAYASHI M: Therapeutic effect of clarithromycin on a transplanted tumor in rats. Antimicrob. Agents Chemothec (1999) 43:67–72.
   PubMed Web of Science ®Google Scholar
• HAMADA K, MIKASA K, YUNOU Y et al: Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemother. (2000) 46:49–61.
   PubMedGoogle Scholar
• YATSUNAMI J, FUKUNO Y,NAGATA M et al.: Antiangiogenesis and antitumor effects of 14-membered ring macrolides antibiotics on mouse B16 melanoma cells. Clin. Exp. Metastasis (1999) 17:361–317.
   Google Scholar
• YATSUNAMI J, FUKUNO Y, NAGATA M et al.: Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. Cancer Lett. (1999) 147:17–24.
   PubMed Web of Science ®Google Scholar
• JACOBS MR, JOHNSON CE: Macrolide resistance: an increasing concern fortreatment failure in children. Pediatric Infect. Dis. J. (2003) 22(8 Suppl.):131–138.
   Google Scholar
• MAEDA K, MIKASA K, KONISHI M et al.: Acute exacerbations due to Streptococcus pneumoniae in chronic lower respiratory infections during long-term macrolide therapy. Kansenshogaku Zasshi (2001) 75:846–850.
   PubMedGoogle Scholar
• PRUNIER AL, MALBRUNY B, LAURANS M, BROUARD J, DUHAMEL JF, LECLERCQ R: High rate of macrolide resistance in Staphylococcus aureus strains in patients with cystic fibrosis reveals high proportions of hypermutator strains. Infect. Dis. (2003) 187:1709–1716.
   Google Scholar
• ••The rise of macrolide (and otherantibiotic) resistance in CF patients.
   Google Scholar